Preston SL - Search Results

1

A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus.

Drusano GL, Preston SL. Drusano GL, et al. Among authors: preston sl. J Infect Dis. 2004 Mar 15;189(6):964-70. doi: 10.1086/382279. Epub 2004 Feb 27. J Infect Dis. 2004. PMID: 14999598 Clinical Trial.

2

Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia.

Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J. Drusano GL, et al. Among authors: preston sl. J Infect Dis. 2004 May 1;189(9):1590-7. doi: 10.1086/383320. Epub 2004 Apr 16. J Infect Dis. 2004. PMID: 15116294 Clinical Trial.

3

Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable.

Drusano GL, Bilello JA, Preston SL, O'Mara E, Kaul S, Schnittman S, Echols R. Drusano GL, et al. Among authors: preston sl. J Infect Dis. 2001 Apr 1;183(7):1126-9. doi: 10.1086/319281. Epub 2001 Mar 1. J Infect Dis. 2001. PMID: 11237841 Clinical Trial.

4

Optimal sampling schedule design for populations of patients.

Tam VH, Preston SL, Drusano GL. Tam VH, et al. Among authors: preston sl. Antimicrob Agents Chemother. 2003 Sep;47(9):2888-91. doi: 10.1128/AAC.47.9.2888-2891.2003. Antimicrob Agents Chemother. 2003. PMID: 12936990 Free PMC article. Clinical Trial.

5

Comparative pharmacokinetic analysis by standard two-stage method versus nonparametric population modeling.

Tam VH, Preston SL, Drusano GL. Tam VH, et al. Among authors: preston sl. Pharmacotherapy. 2003 Dec;23(12):1545-9. doi: 10.1592/phco.23.15.1545.31969. Pharmacotherapy. 2003. PMID: 14695034 Clinical Trial.

6

Guillain-Barré syndrome associated with immune reconstitution.

Piliero PJ, Fish DG, Preston S, Cunningham D, Kinchelow T, Salgo M, Qian J, Drusano GL. Piliero PJ, et al. Clin Infect Dis. 2003 May 1;36(9):e111-4. doi: 10.1086/368311. Epub 2003 Apr 14. Clin Infect Dis. 2003. PMID: 12715328

7

Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens.

Lodise TP, Preston S, Bhargava V, Bryskier A, Nusrat R, Chapel S, Rangaraju M, Drusano GL. Lodise TP, et al. Diagn Microbiol Infect Dis. 2005 May;52(1):45-52. doi: 10.1016/j.diagmicrobio.2004.12.005. Diagn Microbiol Infect Dis. 2005. PMID: 15878442 Clinical Trial.

8

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials.

Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, Reichl V, Natarajan J, Corrado M. Preston SL, et al. JAMA. 1998 Jan 14;279(2):125-9. doi: 10.1001/jama.279.2.125. JAMA. 1998. PMID: 9440662 Clinical Trial.

9

Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.

Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, Reichl V, Natarajan J, Wong FA, Corrado M. Preston SL, et al. Antimicrob Agents Chemother. 1998 May;42(5):1098-104. doi: 10.1128/AAC.42.5.1098. Antimicrob Agents Chemother. 1998. PMID: 9593134 Free PMC article.

10

Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology.

Preston SL, Drusano GL, Glue P, Nash J, Gupta SK, McNamara P. Preston SL, et al. Antimicrob Agents Chemother. 1999 Oct;43(10):2451-6. doi: 10.1128/AAC.43.10.2451. Antimicrob Agents Chemother. 1999. PMID: 10508023 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

84 results

Search Page